TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2015

Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5.

Karim Fizazi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.